Adenosine diphosphate receptor blockade in coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Adenosine diphosphate (ADP) receptor inhibitors, including thienopyridines like clopidogrel and ticlopidine, are vital in preventing major adverse cardiac events.
• Their use before percutaneous coronary intervention (PCI) is established, but optimal management strategies require further clarification.

Purpose of the Study:

• To review current data on the optimal use of ADP receptor inhibitors in the context of PCI.
• To address remaining questions regarding administration timing, dosage, and the role of adjunctive therapies.

Main Methods:

• Review of recent and ongoing clinical studies.
• Analysis of data addressing efficacy and safety of ADP receptor inhibitors around PCI procedures.

Main Results:

• Established benefits of ADP receptor inhibitors in reducing major adverse cardiac events post-PCI.
• Identified ongoing research addressing optimal timing, dosing, and combination therapy strategies.

Conclusions:

• ADP receptor inhibitors are essential for patients undergoing PCI.
• Further research is ongoing to refine optimal treatment protocols, including timing, dosage, and combination therapies, to maximize patient outcomes.